Acadia Pharmaceuticals (ACAD) SEC Filings: History & Chart

Acadia Pharmaceuticals Inc.(ACAD)

Biotechnology · San Diego, CA

$20.10-0.01 (-0.05%)

Delayed quote: Oct 6, 2026, 9:35 AM EDT

About Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

San Diego, CA

797 employees

www.acadia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Catherine E. Owen Adams

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 24, 2026	Sep 24, 2026	View filing
8-K	Sep 11, 2026	Sep 11, 2026	View filing
4	Aug 7, 2026	Aug 7, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
144	Aug 5, 2026	Aug 5, 2026	View filing
10-Q	Aug 5, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
4	Jul 31, 2026	Jul 31, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
144	Jun 26, 2026	Jun 26, 2026	View filing
S-8	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
8-K	May 29, 2026	May 29, 2026	View filing
4	May 27, 2026	May 27, 2026	View filing
144	May 26, 2026	May 26, 2026	View filing
10-Q	May 7, 2026	May 6, 2026	View filing
8-K	May 6, 2026	May 6, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
8-K	May 1, 2026	Apr 30, 2026	View filing
SC 13G	Apr 28, 2026	Apr 28, 2026	View filing
ARS	Apr 24, 2026	Apr 23, 2026	View filing
DEF 14A	Apr 24, 2026	Apr 23, 2026	View filing
4	Apr 7, 2026	Apr 7, 2026	View filing

SEC Filings

Recent Filings